Qdenga dengue vaccine now available in Australia — who should get it

For anyone who has had dengue fever, the phrase “break-bone fever” is not hyperbole — it is a description. The deep joint and bone pain that gives dengue its name is specific enough that clinicians use it as a distinguishing feature from other febrile illnesses. The fatigue that follows can stretch for weeks. Severe dengue, the form involving plasma leakage and fluid accumulation, carries meaningful morbidity and, without adequate access to supportive care, a measurable case fatality rate.

Until recently, the options for prevention in Australia were limited to protective measures: insect repellent, long sleeves, accommodation with air conditioning or screens, and timing travel to avoid peak transmission periods. An earlier dengue vaccine existed but was restricted to people with confirmed prior infection. That restriction has now changed.

Qdenga (TAK-003), a live-attenuated tetravalent dengue vaccine, became available for Australian GPs to order from 1 October 2026, following recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI). It is the first dengue vaccine that can be offered to people without prior confirmed exposure.

What ATAGI recommends — and who it covers

ATAGI’s guidance distinguishes three groups, and the distinctions matter.

Recommended without qualification: people aged 4 and older with confirmed or likely prior dengue infection, travelling to endemic regions. The immune history plus the vaccine together provide meaningful protection across all four dengue serotypes.

Recommended for prolonged or repeated travel: people without prior dengue infection who are planning extended stays or repeated visits to endemic areas. The risk exposure over time justifies the cost and two-visit schedule.

Consider on individual risk-benefit: people without prior infection undertaking short-term travel. This is not a blanket recommendation. According to RACGP newsGP, Dr Peter Markey, Chair of RACGP Specific Interests Public Health, notes the vaccine should be reserved for those with prior infection or high-exposure contexts rather than casual short-stay tourists.

Dosing: two 0.5 mL injections, at least 12 weeks apart. Both doses are required for full protection. The gap is longer than most people’s booking-to-travel window for a booked holiday, which means the conversation needs to happen well ahead of departure.

Why this vaccine matters for Australian travel patterns

Dengue is the fastest-growing communicable disease globally, with approximately 100 million symptomatic cases annually. In Australia, notifications run in the low thousands — 2,381 cases in 2024, 1,863 in 2025 — the vast majority in returning travellers rather than locally-acquired cases. The five countries topping the list of Australians’ travel destinations with frequent or continuous dengue transmission are Indonesia, Thailand, India, Vietnam, and Fiji. These are not remote or unusual destinations. They represent a large proportion of the Australian short-break and annual-leave market.

That context matters for understanding why ATAGI’s recommendation, which is broader than guidelines in several other countries, is clinically defensible. A country whose population regularly and recreationally travels to endemic regions has a different vaccination calculus than one whose exposure is primarily through returned aid workers.

Why this vaccine is different from what came before

Earlier dengue vaccines — most notably Dengvaxia — were restricted to seropositive individuals (those with confirmed prior dengue exposure) because administration to dengue-naïve patients appeared to prime a worse immune response in subsequent natural infection. Qdenga uses a different mechanism and ATAGI has assessed it as appropriate for a broader population, including those without confirmed prior exposure, for higher-risk travel contexts.

The significance is practical. Previous vaccine pathways required serology to confirm prior infection — an additional test, additional cost, and a specialist-level assessment that most GPs could not easily offer. A GP-orderable vaccine that covers both experienced and first-time travellers changes the accessible pathway meaningfully.

Both-and: what advances and what doesn’t

This is a genuine step forward. A live-attenuated tetravalent vaccine covering all four serotypes, available to a broader population, orderable directly by GPs, represents a real improvement on the prior options.

And: Qdenga is not PBS-listed. Patients pay for the vaccine as a private prescription, plus the cost of the GP consultation, on a two-visit schedule. For frequent or long-haul travellers to endemic regions, that cost is likely to be justifiable given the risk. For the average Australian planning a single two-week holiday to Bali, the economics are less clear — which is why ATAGI frames that scenario as an individual risk-benefit discussion rather than a standard recommendation.

It is also worth being clear that no vaccine provides complete protection. Protective measures — repellent applied to exposed skin, long sleeves at dawn and dusk when Aedes mosquitoes are most active, and accommodation that reduces mosquito contact — remain relevant regardless of vaccination status.

2 cents

If you have had dengue before and travel to South-East Asia, the Pacific, South Asia, or sub-Saharan Africa with any regularity, the dengue vaccine conversation belongs at your next GP appointment. The 12-week between-dose gap means the earlier the conversation happens, the more useful it will be before your next trip.

If you have never had dengue and are planning a standard short-stay holiday to Indonesia or Thailand, this is not an automatic next step — but it is a legitimate question to raise with a GP if you are immunocompromised, planning extended travel, or working in a public health or aid context. Individual circumstances determine the calculus.

The access shift is meaningful regardless: a vaccine your GP can order, without requiring a serology workup or a specialist travel clinic referral, is one that reaches more patients.

Verdict: yes — a genuine advance in dengue prevention for travellers with prior exposure and those with regular or prolonged travel to endemic regions.

---

Sources cited

1. Dengue vaccine available in Australia — RACGP newsGP
2. ‘This is a big deal’: Dengue fever vaccine arrives in Australia — AusDoc
3. Dengue and severe dengue fact sheet — WHO